Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Black Diamond Therapeutics, Inc. (BDTX : NSDQ)

• Company Description    Black Diamond Therapeutics Inc. is an oncology medicine company. It engages in discovery and development of small molecule, tumor-agnostic therapies. The company's lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor and tyrosine-protein kinase. Black Diamond Therapeutics Inc. is based in Cambridge, Massachusetts. Number of Employees: 21

• Price / Volume Information    Yesterday's Closing Price: $1.76 Daily Weekly Monthly 20 Day Moving Average: 1,560,626 shares Shares Outstanding: 57.30 (millions) Market Capitalization: $100.85 (millions) Beta: 3.25 52 Week High: $4.94 52 Week Low: $1.60 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 3.53% 2.77% 12 Week -33.58% -35.40% Year To Date -27.57% -30.03%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 245 FIRST STREET 18TH FLOOR - CAMBRIDGE,MA 02142 USA ph: 617-252-0848 fax: - investors@bdtx.com None

• General Corporate Information    Officers Mark A. Velleca - Chief Executive Officer; Chairman; President and D Erika Jones - Senior Vice President Ali Behbahani - Director Samarth Kulkarni - Director Shannon Campbell - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 09203E105 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/06/26 Share - Related Items Shares Outstanding: 57.30 Most Recent Split Date: (:1) Beta: 3.25 Market Capitalization: $100.85 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.05 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.60 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/06/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.97 Price/Cash Flow: 3.34 Price / Sales: - EPS Growth vs. Year Ago Period: -116.33% vs. Previous Quarter: -14.29% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/26 - - 03/31/26 - -30.18 12/31/25 - 23.19 ROA 06/30/26 - - 03/31/26 - -23.91 12/31/25 - 18.48 Current Ratio 06/30/26 - - 03/31/26 - 8.46 12/31/25 - 8.42 Quick Ratio 06/30/26 - - 03/31/26 - 8.46 12/31/25 - 8.42 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - - 12/31/25 - 31.95 Book Value 06/30/26 - - 03/31/26 - 1.82 12/31/25 - 1.97 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©